Form 4: CareDx Director Christine Cournoyer Executes Stock Option and Sells Shares

Christine Cournoyer, a director at CareDx, Inc., exercised stock options and sold shares of common stock on May 12, 2025.

Summary

• On May 12, 2025, Christine Cournoyer, a director of CareDx, Inc., executed a stock option to acquire 29,136 shares of common stock at a price of $7.96 per share.
• Simultaneously, Cournoyer sold 29,136 shares of CareDx common stock at a weighted average price of $15.9604, with individual sales prices ranging from $15.95 to $15.98.
• Following these transactions, Cournoyer directly owns 37,045 shares of CareDx common stock.
• The stock option, which allowed Cournoyer to buy 29,136 shares, vested fully on June 16, 2024, and expires on June 16, 2033.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports a standard insider transaction. The exercise of options and subsequent sale is a common financial activity.

Positives

• The exercise of stock options indicates confidence in the company's future prospects.
• The sale of shares at a higher price than the exercise price generates a profit for the director.

Negatives

• The sale of shares by a director could be interpreted negatively by some investors, although it is a common practice after exercising options.

Risks

• Market fluctuations could impact the value of the remaining shares held by the director.
• Further sales of shares by insiders could put downward pressure on the stock price.

Industry Context

Insider transactions are common in publicly traded companies and are closely monitored by regulators and investors. They can provide insights into management's perspective on the company's valuation and future prospects. However, it's important to consider the context of the transaction, such as the individual's overall holdings and past trading behavior.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly listed companies, and the reporting requirements are standardized by the SEC.
• Comparing Cournoyer's transactions to those of other directors in similar biotech companies could provide a benchmark for assessing the significance of this activity.
• Companies like Exact Sciences (EXAS) and Natera (NTRA) also experience insider trading activity, and analyzing the patterns in those companies could offer a broader perspective.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although it is a common practice after exercising options.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

CareDx, Director, Stock Option, Share Sale, Insider Trading, CDNA, Christine Cournoyer